A 51-year-old woman with stage IV melanoma was enrolled in a tremelimumab study \[[@B1]\]. She was initially diagnosed with malignant melanoma on her back in May 2009. On October 27, 2010, prior to her enrolment in the study, she underwent a transthoracic echocardiography examination. The examination revealed a massive tumour metastasis, probably haematogenic spread through the pulmonary veins, filling out almost the whole left atrium (initial size: fig. [1a](#F1){ref-type="fig"}, fig. [2a](#F2){ref-type="fig"}). In November 2010, a therapy with tremelimumab 15 mg/kg once every 90 days was initiated. Both the patient subjectively and the subcutaneous metastasis responded favourably to the therapy. A follow-up echocardiography 4 weeks later showed regression of the intracardiac metastasis (fig. [2b](#F2){ref-type="fig"}). Moreover, 6 weeks later, the left atrial tumour had completely disappeared (fig. [1b](#F1){ref-type="fig"}, fig. [2c](#F2){ref-type="fig"}). Unfortunately, 2 months later, the patient died at home.

![The parasternal long axis view shows a sessile tumour (\*) filling out almost the whole left atrium (LA) (**a**) prior to tremelimumab therapy. Three months later, the atrial tumour had completely disappeared (**b**). LV = Left ventricle.](cde-0006-0034-g01){#F1}

![**a** The four-chamber view reveals a massive left atrial tumour (\*), probably out of pulmonary veins. **b** Thirty-six days after the first tremelimumab infusion regression of the intracardiac metastasis occurred (arrow). **c** Six weeks later, the left atrial tumour had completely disappeared. LA = Left atrium; LV = left ventricle.](cde-0006-0034-g02){#F2}
